Literature DB >> 15452453

Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre.

A Patócs1, E Karádi, M Tóth, I Varga, N Szücs, K Balogh, J Majnik, E Gláz, K Rácz.   

Abstract

The aims of this study were to estimate the prevalence of phaeochromocytomas among adrenal tumours and to analyse the clinical and biochemical features of sporadic and hereditary tumours. Our series of 609 adrenal tumours evaluated between January 1995 and July 2003 was reviewed. Catecholamine content in phaeochromocytoma tissues was also determined and correlated with clinical behaviour and biochemical parameters of patients. Forty-one (6.7%) of the 609 patients had phaeochromocytomas, of which 28 were sporadic (25 benign and three malignant) and 13 (all benign) were associated with hereditary diseases (multiple endocrine neoplasia type 2A in seven cases from four unrelated families carrying mutations of the RET gene, von Hippel-Lindau disease in two unrelated cases with mutations of the VHL gene, and type 1 neurofibromatosis in four unrelated cases). Bilateral tumours were found in three patients with hereditary syndromes and in one sporadic case. Tumour diameter was slightly but not significantly greater in patients with hereditary than in those with sporadic tumours. Systolic but not diastolic blood pressure was significantly higher in patients with sporadic compared with those with hereditary tumours, but comparison of other clinical data and biochemical parameters indicated an absence of significant differences in the mean age, presenting symptoms, heart rate, or fasting serum glucose levels. Tissue catecholamine content measured in 8 sporadic and 5 hereditary phaeochromocytomas was highly variable and it failed to show significant differences between hereditary and sporadic tumours. These results indicate a high proportion of hereditary diseases among patients with phaeochromocytomas. Genetic and clinical testing for hereditary diseases may be of great help to offer an appropriate treatment, follow-up and family screening for these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452453     DOI: 10.1097/00008469-200410000-00008

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  6 in total

1.  Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.

Authors:  Attila Patócs; Nikoletta K Lendvai; Henriett Butz; Istvan Liko; Zoltan Sapi; Nikolette Szucs; Geza Toth; Vince K Grolmusz; Peter Igaz; Miklos Toth; Károly Rácz
Journal:  Pathol Oncol Res       Date:  2016-03-09       Impact factor: 3.201

2.  Small pheochromocytomas: significance, diagnosis, and outcome.

Authors:  Run Yu; Allison Pitts; Meng Wei
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738

3.  Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome.

Authors:  Nikoletta Lendvai; Miklos Tóth; Zsuzsanna Valkusz; Gabriella Bekő; Nikolette Szücs; Eva Csajbók; Péter Igaz; Balázs Kriszt; Balázs Kovács; Károly Rácz; Attila Patócs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

4.  Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family.

Authors:  Attila Patocs; Peter Gergics; Katalin Balogh; Miklos Toth; Ferenc Fazakas; Istvan Liko; Karoly Racz
Journal:  BMC Med Genet       Date:  2008-04-16       Impact factor: 2.103

Review 5.  Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms.

Authors:  M Pourian; Davani B Mostafazadeh; A Soltani
Journal:  J Diabetes Metab Disord       Date:  2016-03-31

Review 6.  Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms.

Authors:  Akbar Soltani; Mandana Pourian; Babak Mostafazadeh Davani
Journal:  J Diabetes Metab Disord       Date:  2016-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.